If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...
Zacks Investment Research on MSN
CRSP posts wider-than-expected loss in Q4, sales miss estimates
CRISPR Therapeutics CRSP reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results